Disease Progression Study for the Treatment of RRMS
- Study Title
- Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
- Teva Identifier
- 9013
- ClinicalTrials.gov Identifier
- NCT00202995
- Study Status
- Terminated
- Trial Condition(s)
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Drug: Glatiramer Acetate | Drug: Betaseron | Drug: Rebif
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult
- Age Range
- 18 Years to 50 Years
- Trial Duration
- 07/01/2004 - 10/01/2007
- Phase
- Phase 4
